Pharvaris rises after BofA upgrades to Buy (PHVS:NASDAQ)

Pharvaris (PHVS) shares rose 3% premarket after BofA upgraded the stock to Buy from Neutral, citing its oral HAE potential. The brokerage kept its $44 price target. Pharvaris announced in September its.

Original reporting
Published Oct 23, 2026, 11:48 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 23, 2026, 11:53 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefMarket movers
Primary signal
$PHVS
Bullish
high confidence
Mentioned
$PHVS
Relevance
7/10
AlphAI data visualization · based on seekingalpha.com
Decision brief

The 30-second read

$PHVSBullishMed
01

Why it matters

The upgrade may attract short‑term buying, but without fresh product data the rally could be short‑lived.

02

Market read

Analyst upgrade triggers modest pre‑market price gain; relevance primarily for traders focused on small‑cap biotech.

03

What to watch

No new clinical data disclosed; price move driven solely by analyst opinion.

Relevance 7/10Novelty 7/10Timing: pre‑market today

Background

Pharvaris N.V. is a Swiss biotech listed on NASDAQ; recent oral HAE therapy potential cited by BofA.

Company-level read

Ticker impact

$PHVSBullishHigh confidence
Context

BofA upgraded Pharvaris to Buy from Neutral, maintaining a $44 price target; stock rose >3% premarket.

Expected impact

upward pressure as traders price in the upgrade

Evidence & confidence

Analyst upgrade with a maintained target signals confidence in near‑term upside.

Market effects

May lift sentiment for other small‑cap biotech firms awaiting analyst coverage.

Limited to U.S. pre‑market trading; negligible broader regional effect.

Low global relevance beyond niche biotech investors.

Counterpoint

Upgrade could be premature if upcoming trial data disappoints.

Key entities

  • Bank of America

    Upgraded PHVS to Buy, citing oral HAE potential.

Related articles

$PHVSMed

Pharvaris reports Q3 results

Pharvaris reported a Q3 EPS of -$0.67, with cash reserves of €283M as of September 30, 2026, down from €292M at year-end 2025. The company's net loss widened to €47.4M, up from €37.1M year-over-year. Recently, Pharvaris presented at healthcare conferences and announced positive late-stage trial results for its hereditary angioedema drug, leading to an upgrade by BofA to 'Buy'.

$PHVSMedAI 8/10

Pharvaris (PHVS) Reports Q3 Results After Phase 3 Milestone

Pharvaris (PHVS) reported Q3 2026 results, highlighting FDA review of deucrictibant IR NDA with a 2027 PDUFA date. Phase 3 study data for deucrictibant XR expected in 1Q2027. NDA submission for deucrictibant XR in AE-BK attacks planned for 1H2027. Cash position of €283M as of Q3 2026. No financial figures provided for Q3.